Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free!Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
This protein carries a mouse IgG2a Fc tag at the C-terminus.
The protein has a calculated MW of 49.1 kDa. The protein migrates as 70-100 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Human TrkA (192-402), Mouse IgG2a Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
Immobilized Human Beta-NGF Protein, premium grade (Cat. No. BEF-H5214) at 1 μg/mL (100 μL/well) can bind Human TrkA (192-402), Mouse IgG2a Fc Tag (Cat. No. TRA-H5253) with a linear range of 0.1-16 ng/mL (QC tested).
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides innovative solutions for neuroscience research. Recombinant proteins, neural factors, pre-formed fibrils, electrophysiological electrodes, as well as Organoid Toolbox all in Aneuro aiming to advance neuroscience research, develop therapeutic interventions, and improve diagnostic methods for neurological diseases.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Fecha | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Entrectinib | NMS-E628; RXDX-101; RG-6268 | Approved | Nerviano Medical Sciences Srl | Rozlytrek, 罗圣全 | Japan | Carcinoma, Non-Small-Cell Lung | Chugai Pharmaceutical Co Ltd | 2019-06-18 | Cholangiocarcinoma; Melanoma; Thyroid Cancer, Papillary; Carcinoma, Non-Small-Cell Lung; Glioma; Leukemia, Myeloid, Acute; Lymphoma, Large-Cell, Anaplastic; Lymphoproliferative Disorders; Colorectal Neoplasms; Hepatic Insufficiency; Breast Neoplasms; Brain Neoplasms; Solid tumours; Sarcoma; Neuroendocrine Tumors; Central Nervous System Neoplasms; Pancreatic Neoplasms; Salivary Gland Neoplasms; Neoplasms; Carcinoma, Renal Cell; Hematologic Neoplasms; Skin Melanoma; Ovarian Neoplasms; Head and Neck Neoplasms | Details |
Regorafenib | DAST; BAY-73-4506 | Approved | Bayer AG | Stivarga, Resihance | United States | Colorectal Neoplasms | Bayer Healthcare Pharmaceuticals Inc | 2012-09-27 | Fallopian Tube Neoplasms; Osteosarcoma; Sarcoma, Ewing; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Peritoneal Neoplasms; Bone Neoplasms; Bile Duct Neoplasms; Thymoma; Thyroid Neoplasms; Leukemia, Myeloid, Acute; Gastrinoma; Lung Neoplasms; Esophageal adenocarcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma; Gastrointestinal Neoplasms; Somatostatinoma; Adenocarcinoma; Neoplasm Metastasis; Meningioma; Neoplasms; Solid tumours; Ovarian Neoplasms; Rectal Neoplasms; Carcinoma, Renal Cell; Hemangiosarcoma; Carcinoid Tumor; Insulinoma; Carcinoma, Islet Cell; Stomach Neoplasms; Esophageal Neoplasms; Liver Neoplasms; Carcinoma, Transitional Cell; Colonic Neoplasms; Pancreatic Neoplasms; Glioblastoma; Carcinoma, Ovarian Epithelial; Adenoma; Glucagonoma; Carcinoma, Adenoid Cystic; Sarcoma | Details |
Larotrectinib sulfate | LOXO-101; ARRY-470; BAY-2757556 | Approved | Array Biopharma | Vitrakvi, 维泰凯 | United States | Solid tumours | Bayer Healthcare | 2018-11-26 | Glioma; Central Nervous System Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Histiocytosis, Langerhans-Cell; Cholangiocarcinoma; Osteosarcoma; Sarcoma, Ewing; Neuroblastoma; Sarcoma; Histiocytic Sarcoma; Colorectal Neoplasms; Neoplasms, Neuroepithelial; Urinary Bladder Neoplasms; Thyroid Neoplasms; Carcinoma, Squamous Cell; Lymphoma, Non-Hodgkin; Lymphoma; Uterine Neoplasms; Endometrial Neoplasms; Lung Neoplasms; Uterine Cervical Neoplasms; Neoplasms, Germ Cell and Embryonal; Melanoma; Neuroectodermal Tumors, Primitive, Peripheral; Xanthogranuloma, Juvenile; Squamous Cell Carcinoma of Head and Neck; Solid tumours; Ependymoma; Medulloblastoma; Liver Neoplasms; Fibrosarcoma; Leukemia; Rhabdomyosarcoma; Hematologic Neoplasms; Head and Neck Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms; Hepatoblastoma; Rhabdoid Tumor; Rectal Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Wilms Tumor; Colonic Neoplasms; Ski | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Tavilermide | MIM-D3; NMG938VJ6T (UNII code) | Phase 3 Clinical | Mimetogen Pharmaceuticals | Keratoconjunctivitis Sicca; Dry Eye Syndromes | Details |
Lestaurtinib | SPM-924; A-154475.0; KT-5555; SP-924; CEP-701 | Phase 3 Clinical | Kyowa Hakko Kirin Co Ltd | Leukemia, Myeloid; Bone Marrow Neoplasms; Leukemia; Polycythemia Vera; Prostatic Neoplasms; Psoriasis; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Neuroblastoma; Primary Myelofibrosis; Leukemia, Myeloid, Acute; Thrombocythemia, Essential | Details |
SNA-125 | CT-340; SNA-125 | Phase 2 Clinical | Sienna Biopharmaceuticals Inc, Creabilis Sa | Pruritus; Psoriasis; Dermatitis, Atopic | Details |
Merestinib | 5OGS5K699E; LY-2801653 | Phase 2 Clinical | Eli Lilly And Company | Biliary Tract Neoplasms; Skin Melanoma; Bone metastases; Solid tumours; Neoplasms; Pancreatic Neoplasms; Microsatellite instability-high cancer; Lymphoma, Mantle-Cell; Breast Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Gallbladder Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung | Details |
Milciclib maleate | PHA-848125; TZLS-201; PHA-848125C; PHA-125; PHA-848125AC | Phase 2 Clinical | Tiziana Life Sciences Plc, Nerviano Medical Sciences Srl | Solid tumours; Thymoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details |
VC-004 | VC004; VC-004; VC 004 | Phase 2 Clinical | Jiangsu Vcare Pharmatech Co Ltd | Solid tumours; Pruritus; Cancer Pain; Dermatitis; Neoplasm Metastasis | Details |
XZP-5955 | XZP-5955 | Phase 2 Clinical | Xuanzhu (Shijiazhuang) Biotechnology Co Ltd | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
BEN-2293 | BEN-00002293; BEN-2293 | Phase 2 Clinical | Benevolentai Bio Ltd | Dermatitis, Atopic | Details |
TQB-3558 | TQB-3558; CT-3417 | Phase 1 Clinical | Beijing Centaurus Biopharma Co Ltd, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | Solid tumours | Details |
ACD-856 | ACD-856 | Phase 1 Clinical | Alzecure Pharma Ab | Alzheimer Disease; Cognition Disorders | Details |
HG-030 | HG-030 | Phase 1 Clinical | Hitgen Inc | Solid tumours | Details |
AK-1830 | AK-1830 | Phase 1 Clinical | Array Biopharma | Inflammation | Details |
BR-01T | BR01T; BR-01T | Phase 1 Clinical | Xiyuan Anjian Pharmaceutical (Shanghai) Co Ltd | Low Back Pain | Details |
ND-003 (NewDEL Biotech) | ND-003; ND003 | Phase 1 Clinical | Shenzhen NewDEL Biotech Co Ltd | Solid tumours; Neoplasms; Idiopathic Pulmonary Fibrosis; Renal fibrosis; Pulmonary Fibrosis; Renal Insufficiency, Chronic; Dermatitis, Atopic | Details |
JND-5932 | JND-5932; JND5932 | Phase 1 Clinical | Jinan University | Neoplasms | Details |
PBI-200 | PBI-200 | Phase 1 Clinical | Pyramid Biosciences | Solid tumours; Desmoplastic Small Round Cell Tumor; Brain Neoplasms | Details |
TQB-3811 | TQB-3811; CT-3872 | Phase 1 Clinical | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd, Beijing Centaurus Biopharma Co Ltd | Solid tumours | Details |
FCN-098 | FCN-098; FCN098 | Phase 1 Clinical | Fochon Pharmaceuticals Ltd, Fochon Pharmaceuticals Ltd | Solid tumours; Neoplasms | Details |
E-2511 | E2511; E-2511 | Phase 1 Clinical | Eisai Inc | Details | |
Beta-Nerve Growth Factor, Human (Aalborg University) | Phase 1 Clinical | Aalborg University Shakespeare Company | Pain; Hyperalgesia | Details | |
Recombinant human nerve growth factor (Beijing Tongren Hospital) | Phase 1 Clinical | Beijing Tongren Hospital, Cmu | Optic Nerve Injuries | Details | |
VMD-928 | VMD-928 | Phase 1 Clinical | Vm Oncology Llc | Head and Neck Neoplasms; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Urinary Bladder Neoplasms; Mesothelioma; Carcinoma, Adenoid Cystic; Sarcoma; Breast Neoplasms; Thymoma; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
This web search service is supported by Google Inc.